Mon. Sep 26th, 2022

 

 

“DelveInsight’s, “Dry Age-Related Macular Degeneration Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Dry Age-Related Macular Degeneration Pipeline landscape”

It covers the Dry Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dry Age-Related Macular Degeneration therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Dry Age-Related Macular Degeneration emerging drugs, the Dry Age-Related Macular Degeneration pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Dry Age-Related Macular Degeneration pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key takeaways from the Dry Age-Related Macular Degeneration Pipeline Insight Report

  • DelveInsight’s Dry Age-Related Macular Degeneration Pipeline analysis depicts the space with 40+ active players working to develop 40+ pipeline therapies.
  • The Dry Age-Related Macular Degeneration Pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.
  • Dry Age-Related Macular Degeneration pipeline companies include IVERIC bio, Alkeus Pharmaceuticals, Gyroscope Therapeutics, Gemini Therapeutics, Regenerative Patch Technologies, OliX Pharmaceuticals, Eyestem, and others.
  • Dry Age-Related Macular Degeneration pipeline therapies in different stages of development include Zimura, ALK-001, GT005, GEM103, CPCB-RPE1, OLX301A, Eyecyte RPE, and others.
  • Dry Age-Related Macular Degeneration pipeline therapeutics assessment includes Assessment by product type, By Stage and product type, Route of administration, By stage and route of administration, By Molecule Type, By stage, and Molecule Type, Mechanism of action, By stage and mechanism of action, Assessment by targets, By Stage and Targets.

Get to know more in-depth information about the Dry Age-Related Macular Degeneration Pipeline Report, click here @ Dry Age-Related Macular Degeneration Pipeline Insight

Dry Age-Related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. “Age-related” means that it mainly occurs with elderly adults, while “Macular” means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago. Dry macular degeneration is a common eye disorder among people aged above 50 years. It causes blurred or reduced central vision due to thinning of the macula. The macula is the part of the retina responsible for clear vision in a direct line of sight. GA or choroidal neovascularization are two processes that produce photoreceptor failure in late AMD and can cause visual loss.

Usually, dry AMD progresses very slowly whereas, some people experience severe visual impairment within days or weeks of the onset of wet AMD. The diagnostic methods of AMD include fundus imaging, fluorescein angiogenesis (FA), indocyanine green angiography (ICGA), optical coherence tomography (OCT), Optical coherence tomography angiography (OCTA), and artificial intelligence (AI). These techniques play an important role in the diagnosis of AMD and have their unique advantages. A detailed understanding of the molecular mechanisms underlying wet AMD has led to several robust FDA-approved therapies. In contrast, there are not any approved treatments for dry AMD. The management of dry AMD consists of observation, regular follow-up evaluations, and documentation for timely recognition of visual function deterioration with appropriate rehabilitation and early CNV detection.

Dry Age-Related Macular Degeneration Pipeline Insight Report

Dry Age-Related Macular Degeneration Pipeline Insight 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Age-Related Macular Degeneration pipeline landscape is provided which includes the disease overview and Dry Age-Related Macular Degeneration treatment guidelines. The assessment part of the report embraces, in depth Dry Age-Related Macular Degeneration commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Age-Related Macular Degeneration collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Dry Age-Related Macular Degeneration Emerging Drugs

  • ALK-001: Alkeus Pharmaceuticals
  • Zimura: Iveric bio
  • Visomitin: Mitotech
  • Risuteganib: Allegro Ophthalmics
  • GT005: Gyroscope Therapeutics
  • GEM103: Gemini Therapeutics

Dry Age-Related Macular Degeneration Pipeline Therapeutic Analysis

There are approx. 40+ key companies which are developing the therapies for Dry Age-Related Macular Degeneration. The companies which have their Dry Age-Related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.

For further information about Dry Age-Related Macular Degeneration Treatment and pipeline therapies, visit @ Dry Age-Related Macular Degeneration Pipeline Assessment

Dry Age-Related Macular Degeneration Pipeline Phases

DelveInsight’s Report covers around 40+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Dry Age-Related Macular Degeneration Pipeline development activities

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Dry Age-Related Macular Degeneration with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage, and late stages of development for the Dry Age-Related Macular Degeneration
  • Dry Age-Related Macular Degeneration key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development are based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of Dry Age-Related Macular Degeneration

The Dry Age-Related Macular Degeneration Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Table of Content

  1. Introduction
  2. Executive Summary
  3. Dry Age-Related Macular Degeneration: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. ALK-001: Alkeus Pharmaceuticals
  8. Mid Stage Products (Phase II)
  9. Visomitin: Mitotech
  10. Early stage products (Phase I/II)
  11. RPESC-RPE-4W: Luxa Biotechnology
  12. Inactive Products
  13. Dry Age-Related Macular Degeneration Key Companies
  14. Dry Age-Related Macular Degeneration Key Products
  15. Dry Age-Related Macular Degeneration- Unmet Needs
  16. Dry Age-Related Macular Degeneration- Market Drivers and Barriers
  17. Dry Age-Related Macular Degeneration- Future Perspectives and Conclusion
  18. Dry Age-Related Macular Degeneration Analyst Views
  19. Dry Age-Related Macular Degeneration Key Companies
  20. Appendix

Got Queries? Reach out for more information on the Dry Age-Related Macular Degeneration Pipeline Report- Dry Age-Related Macular Degeneration Clinical Trials

You may explore our latest Pharmaceutical Market Research Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: [email protected]
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

By krehani

Leave a Reply

Your email address will not be published. Required fields are marked *